EMEA-003068-PIP01-21
Key facts
| Active substance |
Adagrasib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0511/2021
|
| PIP number |
EMEA-003068-PIP01-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of all solid and haematological malignancies
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Mirati Therapeutics, Inc.
Email: albrighta@mirati.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|